> Detailanzeige

Strzelczyk, Adam; Zöllner, Johann Philipp; Willems, Laurent M.; Jost, Julie; Paule, Esther; Schubert‐Bast, Susanne; Rosenow, Felix; Bauer, Sebastian

Lacosamide in status epilepticus: Systematic review of current evidence

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Lacosamide in status epilepticus: Systematic review of current evidence
  • Beteiligte: Strzelczyk, Adam; Zöllner, Johann Philipp; Willems, Laurent M.; Jost, Julie; Paule, Esther; Schubert‐Bast, Susanne; Rosenow, Felix; Bauer, Sebastian
  • Erschienen: Wiley, 2017
  • Erschienen in: Epilepsia
  • Sprache: Englisch
  • DOI: 10.1111/epi.13716
  • ISSN: 0013-9580; 1528-1167
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Summary</jats:title><jats:sec><jats:title>Objective</jats:title><jats:p>The intravenous formulation of lacosamide (<jats:styled-content style="fixed-case">LCM</jats:styled-content>) and its good overall tolerability and safety favor the use in status epilepticus (<jats:styled-content style="fixed-case">SE</jats:styled-content>). The aim of this systematic review was to identify and evaluate studies reporting on the use of <jats:styled-content style="fixed-case">LCM</jats:styled-content> in <jats:styled-content style="fixed-case">SE</jats:styled-content>.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We performed a systematic literature search of electronic databases using a combined search strategy from 2008 until October 2016. Using a standardized assessment form, information on the study design, methodologic framework, data sources, efficacy, and adverse events attributed to <jats:styled-content style="fixed-case">LCM</jats:styled-content> were extracted from each publication and systematically reported.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>In total, 522 <jats:styled-content style="fixed-case">SE</jats:styled-content> episodes (51.7% female) in 486 adults and 36 children and adolescents were evaluated with an overall <jats:styled-content style="fixed-case">LCM</jats:styled-content> efficacy of 57%. Efficacy was comparable between use in nonconvulsive (57%; 82/145) and generalized‐convulsive (61%; 30/49; p = 0.68) <jats:styled-content style="fixed-case">SE</jats:styled-content>, whereas overall success rate was better in focal motor <jats:styled-content style="fixed-case">SE</jats:styled-content> (92%; 34/39, p = 0.013; p &lt; 0.001). The efficacy with later positioning of <jats:styled-content style="fixed-case">LCM</jats:styled-content> decreased from 100% to 20%. The main adverse events during treatment of <jats:styled-content style="fixed-case">SE</jats:styled-content> are dizziness, abnormal vision, diplopia, and ataxia. Overall, lacosamide is well tolerated and has no clinically relevant drug–drug interactions.</jats:p></jats:sec><jats:sec><jats:title>Significance</jats:title><jats:p>The available data regarding the use of <jats:styled-content style="fixed-case">LCM</jats:styled-content> in <jats:styled-content style="fixed-case">SE</jats:styled-content> are promising, with a success rate of 57%. The strength of <jats:styled-content style="fixed-case">LCM</jats:styled-content> is the lack of interaction potential and the option for intravenous use in emergency situations requiring rapid uptitration.</jats:p></jats:sec>
  • Zugangsstatus: Freier Zugang